Edgewise Therapeutics, Inc. EWTX
46.59 USD -0.98 (-2.06%)
Nov 12, 2026, 12:52 PM EST
45.07 Day range 46.93
19.76 52-week range 48.78
- YTD
- +87.71%
- 1 year
- +120.08%
News
prnewswire.com Edgewise Therapeutics to Participate in Upcoming Investor Conferences BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management will…
benzinga.com Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51 Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $53 to $51.
benzinga.com Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 Meeting – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO₂ as the primary endpoint…
prnewswire.com Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring – Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two…
benzinga.com Edgewise Therapeutics Q3 Adj. EPS $(0.19) Misses $2.48 Estimate Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $2.48 by 107.66 percent. This is a 51.28 percent increase over losses…
benzinga.com William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating.- benzinga.com Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a…
- benzinga.com HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57 HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.
- benzinga.com Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36 Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.
- benzinga.com Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.47) by 12.77 percent. This is a 55.88 percent decrease over…
benzinga.com Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55 Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.
benzinga.com Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51 Oppenheimer analyst Mazahir Alimohamed initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating and announces Price Target of $51.- benzinga.com Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51 Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $41 to $51.
benzinga.com Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
benzinga.com RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59 RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $59.- benzinga.com Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J B Hunt, Needham for Glaukos, B of A for CSX, Morgan Stanley for Charles River, and Bernstein for…
benzinga.com Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $32 Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $20 to $32.
benzinga.com Edgewise Therapeutics Reports Improvements In Heart Drug Trial Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.- benzinga.com HC Wainwright & Co. Reiterates Buy on Edgewise Therapeutics, Maintains $45 Price Target HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and maintains $45 price target.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Edgewise Therapeutics Says Topline Data From 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 In Obstructive And Nonobstructive Hypertrophic Cardiomyopathy Show No Relationship Observed Between Multiple Measures Of Systolic Function And Concentration Of EDG-7500 – No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% –– Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers,…
- benzinga.com HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $45 HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $42 to $45.
- benzinga.com RBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $48 RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $50 to $48.
- benzinga.com Wedbush Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $52 Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $46 to $52.
benzinga.com Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy, and aerospace stocks saw notable gains.- benzinga.com Edgewise To Sell Its Muscular Dystrophy Business To Servier For $1.55B In Cash Up Front And Up To $1.1B In Further Milestone Payments For Aggregate Potential Sum Of Up To $2.65B The transaction meaningfully strengthens Edgewise's balance sheet, providing enhanced financial flexibility and sharpening the Company's strategic focus to accelerate and unlock the full potential of…
benzinga.com Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidance. Other big gainers include EverQuote, Sterling Infrastructure, and DigitalOcean.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Gold Edges Lower; Omeros Shares Jump
benzinga.com Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
- benzinga.com Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
benzinga.com Crude Oil Gains Over 1%; Mobileye Global Shares Jump - benzinga.com Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
- benzinga.com Market-Moving News for September 19th GLMD: 60% | Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years EWTX: 42% | Edgewise Therapeutics Announced Top-line…
- benzinga.com Insiders Buying Edgewise Therapeutics And 2 Other Stocks Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
- benzinga.com Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per…
- benzinga.com Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
- benzinga.com Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 215 companies set new 52-week lows.